Healthpeak Properties stock (US42226K1051): Hits 52-week high on analyst upgrades

Healthpeak Properties shares reached a new 52-week high of $19.91 on NYSE after UBS Group raised its price target from $17 to $19, with further upgrades from Robert W. Baird and Citigroup.

Healthpeak Properties stock surged to a new 52-week high of $19.91 during mid-day trading on Thursday, May 14, 2026, following an analyst upgrade from UBS Group, which lifted its price target from $17.00 to $19.00 while maintaining a neutral rating, according to MarketBeat as of 05/14/2026. Robert W. Baird also raised its target from $19.00 to $21.00 with an outperform rating on May 13, while Citigroup increased its objective from $17.50 to $20.00 with a neutral rating on May 12. The stock last traded at $19.78 with volume over 1.5 million shares.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Healthpeak Properties
• Sector/industry: Real Estate / Healthcare REIT
• Headquarters/country: Irvine, California, USA
• Core markets: US healthcare properties
• Key revenue drivers: Rentals from life science, medical office, post-acute care
• Home exchange/listing venue: NYSE (DOC)
• Trading currency: USD

Healthpeak Properties: core business model

Healthpeak Properties owns, develops, and acquires a diversified portfolio of healthcare-related real estate properties focused on life science, medical office, and post-acute care facilities. Headquartered in Irvine, California, the company targets properties serving the evolving needs of the healthcare industry across the United States, according to its corporate profile as of 05/14/2026.

The REIT generates revenue primarily through long-term leases to healthcare operators, research institutions, and medical providers. This model provides stable cash flows backed by demographic trends like aging populations and increased demand for specialized medical infrastructure.

Main revenue and product drivers for Healthpeak Properties

Healthpeak Properties' key revenue comes from rental income on its portfolio of life science labs, medical office buildings, and senior housing communities. In the most recent quarter reported, the company achieved earnings per share of $0.45, surpassing consensus estimates of $0.43, with quarterly revenue up 7.1% year-over-year, per financial disclosures referenced on MarketBeat as of 05/14/2026.

Growth drivers include expansion in high-demand life science assets, which benefit from biotech innovation hubs in key US markets, alongside steady occupancy in medical offices serving outpatient care.

Industry trends and competitive position

The healthcare REIT sector benefits from resilient demand amid rising healthcare spending, projected to grow with US population aging. Healthpeak Properties holds a strong position with its focus on life sciences, a subsector seeing robust leasing activity from research and development firms.

Why Healthpeak Properties matters for US investors

Listed on the NYSE, Healthpeak Properties offers US investors exposure to healthcare real estate, a defensive asset class with ties to the $4 trillion US healthcare economy. Its dividend yield around 6.14% as of recent trading data from Google Finance as of 05/14/2026 appeals to income-focused portfolios amid market volatility.

Conclusion

Healthpeak Properties stock has shown upward momentum with a new 52-week high driven by multiple analyst price target increases from UBS Group, Robert W. Baird, and Citigroup in recent days. The company's solid earnings beat and focus on healthcare real estate position it within a growing sector relevant to US investors. Market reactions reflect optimism, though consensus remains a Hold with an average target of $18.75.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.